BioCryst Pharmaceuticals | BCRX - Trade Debtors


BioCryst Pharmaceuticals reported $106.82M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Chugai Pharma JPY 352.94B 90.17B Mar/2026
Daiichi Sankyo JPY 695.95B 79.1B Dec/2025
DBV Technologies USD 15.1M 1.05M Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Gilead Sciences USD 4.74B 172M Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Novavax USD 106.45M 72.27M Dec/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Roche Holding CHF 11.9B 460M Dec/2025
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026